期刊文献+

慢性丙型肝炎患者抗病毒治疗后甲状腺功能动态变化和转归及其影响因素 被引量:7

Thyroid function of patients with chronic hepatitis C after antiviral treatment:dynamic changes,prognosis and influencing factors
下载PDF
导出
摘要 目的:探讨慢性丙型肝炎(CHC)患者抗病毒治疗后甲状腺功能动态变化和转归,阐明基线因素对甲状腺功能改变的影响。方法:取基线甲状腺功能正常的CHC患者243例,均给予干扰素-α2b联合利巴韦林抗病毒治疗48周,分别在12、24、36、48、60和72周时对甲状腺功能和HCV RNA定量等进行检测,根据治疗后甲状腺功能变化情况分为持续正常组、亚临床甲状腺功能减退(亚甲减)组、甲状腺功能减退(甲减)组和甲状腺功能亢进(甲亢)组,观察各组患者甲状腺功能变化的规律。结果:82例(33.7%)患者发生甲状腺功能改变,其中亚甲减51例(20.9%),甲减13例(5.3%),甲亢18例(7.4%)。随访至72周时,亚甲减、甲减、甲亢患者恢复正常的分别为32例(39.0%)、12例(14.6%)和7例(8.5%),甲减转变为亚甲减的为6例(7.3%),甲亢转变为亚甲减的为3例(3.7%);19例(23.2%)患者病情无明显改善,1例(1.2%)表现为持续亚甲减,13例(15.9%)持续甲减,5例(6.1%)持续甲亢;3例(3.7%)患者由甲亢转变为甲减。女性甲减发生率高于男性(P<0.05);发生甲亢患者平均年龄低于甲减、亚甲减及持续正常患者(P<0.05);发生甲亢和甲减患者基线γ-谷氨酰转肽酶水平低于亚甲减和持续正常者(P<0.05);发生甲亢患者中HCV 2a型患者所占比例明显高于发生甲减、亚甲减及持续正常者(P<0.05)。结论:CHC患者抗病毒治疗可使甲状腺功能发生改变,性别、年龄、肝功能和基因型对甲状腺功能改变具有预测意义。 Objective To investigate the dynamic changes and prognosis of thyroid function in the patients with chronic hepatitis C (CHC)after antiviral treatment,and to clarify the influence of baseline factors in the changes of thyroid function.Methods 243 CHC patients with normal baseline thyroid function were enrolled. All patients were treated with IFN-alpha-2b(IFN-α2b)combined with ribavirin for 48 weeks.The thyroid function and serum HCV RNA level were assessed at 12,24,36,48,60 and 72 weeks.According to the changes in thyroid function after treatment,the patients were divided into continued normal,subclinical hypothyroidism,hypothyroidism and hyperthyroidism groups.The regularity of the changes of thyroid function of the patients in various groups were observed.Results Among 243 CHC patients,82(33.7%)patients had thyroid dysfunction.The prevalence of&amp;nbsp;subclinical hypothyroidism,hypothyroidism and hyperthyroidism were 20.9%(51/243),5.3%(13/243)and 7.4%(18/243),respectively. At the end of 72 weeks,there were 32 (39.0%)patients suffering from subclinical hypothyroidism,12 (14.6%) patients with hypothyroidism and 7 (8.5%) patients with hyperthyroidism rehabilitated.6(7.3%)patients suffering from hypothyroidism turned to subclinical hypothyroidism,and 3(3.7%) patients suffering from hyperthyroidism turned to subclinical hypothyroidism.19(23.2%)patients had no significant change,they performed for continued subclinical hypothyroidism (1,1.2%),hypothyroidism (13,15.9%)and hyperthyroidism (5 , 6.1%).In addition, 3 (3.7%)patients with hyperthyroidism turned to hypothyroidism.An increased risk for hypothyroidism was found in female patients compared with males (P〈0.05);the average age of the patients with hyperthyroidism was lower than those of the patients with hypothyroidism, subclinical hypothyroidism and continued normal (P〈0.05);the baseline levels of GGT in the patients with hyperthyroidism and hypothyroidism were lower than those of the patients with subclinical hypothyroidism and continued normal(P〈0.05).The ratio of the patients with HCV 2a to the patients with hypertyroidism was higher than those of the patients with hypothyroidism,subclinical hypothyroidism and continued normal(P〈0.05).Conclusion Thyroid function in the CHC patients can be affected by antiviral treatment. Gender, age, liver function, genotype of HCV are influencing factors for the changes of thyroid function.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2014年第3期641-645,共5页 Journal of Jilin University:Medicine Edition
基金 国家自然科学基金资助课题(81072347)
关键词 肝炎 丙型 慢性 抗病毒治疗 甲状腺功能 干扰素-Α2B 利巴韦林 hepatitis C, chronic antiviral treatment thyroid function interferon α-2b ribavirin
  • 相关文献

参考文献17

  • 1石晓东,姜晶,牛俊奇.白细胞介素28B的基因多态性与丙型肝炎病毒感染转归的关系[J].临床肝胆病杂志,2011,27(1):28-31. 被引量:11
  • 2Kajiyama Y,Kikuchi K,Takai A,et al.B-cell-activating factor affects the occurrence of thyroid autoimmunity in chronic hepatitis C patients treated with interferon alpha[J].Clin Dev Immunol,2012,2012:247973.doi:10.1155/2012/247973.
  • 3Yan Z,Fan K,Fan Y,et al.Thyroid dysfunction in chinese patients with chronic hepatitis C treated with interferon alpha:incidence,long-term outcome and predictive factors[J].Hepat Mon,2012,12(9):e6390.
  • 4赵平,王江滨,焦健.慢性丙型肝炎患者合并肝外自身免疫现象及自身抗体分析在与自身免疫性肝炎鉴别诊断中的意义[J].中国老年学杂志,2010,30(15):2097-2099. 被引量:10
  • 5Mandac JC,Chaudhry S,Sherman KE,et al.The clinical and physiological spectrum of interferon-alpha induced thyroiitis:toward a new classification[J].Hepatology,2006,43(4):661-672.
  • 6Tran HA,Jones TL,Ianna EA,et al.Thyroid disease in chronic hepatitis C infection treated with combination interferon-αand ribavirin:management strategies and future perspective[J].Endocr Pract,2012,19(2):292-300.
  • 7霍娜,王力芬,范晓红,陆海英,徐小元.慢性丙型肝炎患者甲状腺功能异常情况观察[J].传染病信息,2011,24(2):97-99. 被引量:9
  • 8Devdhar M,Ousman YH,Burman KD.Hypothyroidism[J].Endocrinol Metab Clin North Am,2007,36(3):595-615.
  • 9Arrigo T,Wasniewska M,Crisafulli G,et al.Subclinical hypothyroidism:the tate of the art[J].J Endocrinol Invest,2008,31(1):79-84.
  • 10Deutsch M,Dourakis S,Manesis EK,et al.Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy[J].Hepatology,1997,26(1):206-210.

二级参考文献51

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2连小兰,白耀,孙梅励,郭芝生,戴为信.血清抗甲状腺球蛋白抗体和抗甲状腺过氧化物酶抗体测定的临床诊断意义[J].中国医学科学院学报,2004,26(6):677-681. 被引量:38
  • 3陈智,潘修成.丙型肝炎与自身免疫性疾病[J].中华肝脏病杂志,2006,14(3):236-237. 被引量:25
  • 4蔡晓频,杨文英.药源性甲状腺疾病[J].药物不良反应杂志,2006,8(3):206-209. 被引量:11
  • 5Mouelhi L,Debbeche R,Sfar I,et al.Auto-immune serological disorders in chronic viral C hepatitis:prevalence and clinical significance[J].Tunis Med,2008;86(9):777-81.
  • 6EL-Serag HB,Hampel H,Yeh C.Extrahepatic manifestations of hepatitis C among United States male veterans[J].Hepatology,2002;36:1439-45.
  • 7De Riva V,Celadin M,Pittoni M,et al.What is behind the presence of anti-neutrophil cytoplasmatic antibodies in chronic liver disease[J]?Liver Int,2009;29(6):865-70.
  • 8Antonelli A,Ferri C,Ferrari SM,et al.Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia[J].Autoimmun Rev,2008;8(1):18-23.
  • 9Cacoub P,Renou C,Rosenthal E,et al.Extrahepatic manifestations associated with hepatitis C virus infection:a prospective multi-center study of 321 patients[J].Medicine (Baltimore),2000;79:47-56.
  • 10Tomer Y.Hepatitis C and interferon induced thyroiditis[J].J Autoimmun,2010;34(3):J322-6.

共引文献25

同被引文献70

  • 1陆小蒟,陈永平,阳韬,程瑗,金晓芝,申春燕,刘俊,王春莹,王晓东,林镯.调节性T细胞对肝星状细胞增殖及透明质酸分泌的影响[J].临床肝胆病杂志,2012,28(1):39-43. 被引量:3
  • 2丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 3中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志,2007,46(10):876-882. 被引量:835
  • 4刘鍈,袁辉,杜媛媛,等.甲亢性肝功能损害的临床特点和相关因素分析[J].中国医师杂志,2014,45(1):135-136.
  • 5Si Wu,Yue Gao,Xin Dong,et al. Serum metabonomicscoupled with ingenuity pathway analysis characterizesmetabolic perturbations in response to hypothyroidisminduced by propylthiouracil in rats[J]. Journal of Phar-maceutical and Biomedical Analysis ,2013,72(6) ; 109-114.
  • 6Maria Klatka’Ewelina Grywalska, Malgorzata Partyka. Im-pact of methimazole treatment on magnesium concentra-tion and lymphocytes activation in adolescents withGraves' disease [J]. Biological Trace Element Research,2013, 153(13):155-170.
  • 7GENTILE I, BUONOMO AR, ZAPPULO E, et al. Interferonfree therapies for chronic hepatitis C: toward a hepatitis C virus -free world?[J]. Expert Rev Anti Infect Ther, 2014, 12 ( 7) : 763 - 773.
  • 8PAWLOTSKYJM. New hepatitis C therapies: the toolbox, strategies, and challenges[J]. Gastroenterology, 2014, 146 ( 5) : 1176 -1192.
  • 9HADZIYANNIS SJ, SETTE HJr, MORGAN TR, et al. Peginterferon -alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose[J]. Ann Intem Med, 2004, 140(5): 346 -355.
  • 10DIETERICH DT, RIZZETIO M, MANNS MP. Managementof chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin[J].J Viral Hepat, 2009,16(12): 833 -843.

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部